GEN Poll Majority Favors Moratorium on Synthetic Bio Products
By GEN,
Genetic Engineering & Biotechnology News
| 04. 10. 2012
A majority of respondents to a recent GEN poll would like to see a moratorium on synthetic biotechnology products pending further regulations being put into place. 55.2% of respondents agreed with a group of 111 watchdog organizations including ETC Group and Friends of the Earth, which last month issued a report that called synthetic biology “an extreme form of genetic engineering” and asked for a moratorium on the release and commercial use of synthetic organisms and their products.While 3.9% of respondents were undecided about their position on this matter, 40.9%, did not feel the need for a moratorium.
Synthetic bio is among the latest examples of a scientific achievement that has generated as much fear among portions of the public as did DNA technology and stem cells. Over the years, however, those fears have been addressed by organizations assessing the risks and monitoring potential hazards of new biotechnologies.
Related Articles
By Virginia Heffernan, The New Republic | 05.29.2026
Here and there, it’s been a good month for humanity—or “magnificas humanitas,” as Pope Leo XIV calls us poor featherless bipeds.
On May 25, the pope published his encyclical letter “on safeguarding the human person in the time of artificial...
By Sonya Borrero, Christine Dehlendorf, and Rachel Logan, Stat | 05.01.2026
America is worried about fertility rates — again.
Coverage of the country’s declining birth rate reflects widespread unease: Families are struggling, young adults are delaying or forgoing parenthood, and the future labor force feels uncertain. These concerns are rooted in...
By Emile P. Torres, Truthdig | 04.27.2026
The CEO of OpenAI, Sam Altman, is on a messianic mission to bring about the singularity, the moment at which artificial intelligence begins to self-improve. If AI is smart enough to build the next generation of even smarter AI...
By Marcelo Jauregui-Volpe, Wired | 04.24.2026
Two companies that launched last year with plans to create gene-edited babies have already shut down, citing money issues and internal conflict.
One of them, Manhattan Genomics of New York, closed abruptly shortly after announcing a team of scientific advisers...